NasdaqGM:RNABiotechs
Assessing Avidity Biosciences (RNA) Valuation After Its Strong Multi‑Year Share Price Rally
Avidity Biosciences (RNA) has quietly turned into a strong performer, with the stock up sharply this year as investors warm to its RNA therapeutic platform and advancing muscular dystrophy pipeline.
See our latest analysis for Avidity Biosciences.
That surge in optimism is showing up in the numbers, with a roughly 49 percent 3 month share price return feeding into a powerful 129 percent year to date share price gain and an eye catching 3 year total shareholder return above 550 percent. This...